chemieunternehmen.com

Evotec SE, LabCentral, a launchpad for high-potential life science and biotech start-ups, BioLabs, an international membership based network of shared lab and office facilities, and MBC BioLabs, premier providers of co-working laboratory space, today announced an agreement to boost early-stage innovations through access to Evotec’s leading shared end-to-end R&D platform.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-launch-of-partnering-agreement-to-strengthen-biotech-innovators-in-shared-rd-economy-6326

Evotec SE and Novo Nordisk today announced LAB eN², a translational drug discovery accelerator that aims to nurture early research from academic institutions into novel therapeutics. The focus is on addressing unmet need in cardiometabolic diseases as well as rare blood and rare endocrine disorders. LAB eN² is a unique engagement model that combines Evotec’s multimodality drug discovery and pre-clinical development capabilities with Novo Nordisk’s therapeutic, clinical, and commercial expertise. LAB eN² has already signed on four academic institutions to participate: Harvard University, Mass General Brigham, Yale University, and Beth Israel Deaconess Medical Center. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-novo-nordisk-launch-lab-en2-to-accelerate-translation-in-cardiometabolic-diseases-6324

Evotec SE today announced its financial results and corporate updates for the first half-year of 2023. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-reports-results-for-the-first-half-year-2023-and-provides-corporate-updates-6322

Evotec SE will announce its financial results for the first half-year of 2023 on Tuesday, 29 August 2023. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-reports-first-half-year-2023-results-on-29-august-2023-6320

Evotec today announced that its partner STORM Therapeutics Ltd. (“STORM”), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, will be presenting the discovery of its lead clinical candidate, STC-15, at the American Chemical Society (ACS) Fall 2023 Conference. STC-15, an orally bioavailable and highly selective METTL3 inhibitor, was co-designed and developed through a collaboration between STORM and Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-partner-storm-therapeutics-to-present-the-discovery-of-lead-clinical-candidate-stc-15-at-the-american-chemical-society-fall-2023-conference-6318

Evotec SE today announced that it is adjusting its guidance for the fiscal year 2023 due to the impact of the cyber-attack.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-provides-update-on-financial-impact-of-cyber-attack-6314

Evotec SE today announced that Bristol Myers Squibb Company has exercised its option to enter into an exclusive global licence agreement. The licence covers selected late-stage discovery programmes that were developed and progressed within the collaboration. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-bristol-myers-squibb-enter-licence-agreement-within-neuroscience-partnership-6312

Evotec SE today announced that the U.S. Department of Defense (“DOD”) has awarded Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc. a contract valued up to $ 74 m for the rapid development of monoclonal antibody (“mAb”)-based drug product prototypes targeting orthopoxviruses. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/just—evotec-biologics-awarded-second-contract-from-us-department-of-defense-under-accelerated-antibodies-program-6310

Evotec SE announced today that it is to receive a € 2 m milestone payment from Bayer AG, which is triggered by the first patient dosed in the clinical Phase I study of a kidney disease programme stemming from the Evotec-Bayer multi-target research collaboration in kidney diseases. The drug candidate, a monoclonal antibody (“mAb”) targeting the protein Semaphorin-3A (“Sema3A”) is being developed as a potential first-to-market treatment for Alport syndrome, a rare genetic kidney disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-milestone-payment-for-first-patient-dosed-in-phase-i-study-of-bayer-kidney-disease-programme-6308